However, GSIs are still being widely investigated as cancer therapies in preclinical studies and have shown antitumor activity in a variety of cancers, such as hepatocellular carcinoma, where the use of the γ-secretase inhibitor DAPT or the combination of DAPT with the CD147-directed antibody HAb18 has been shown to be effective in the treatment of human HCC tumors transplanted in situ (104). This evidence concerns the gene BSG and hepatocellular carcinoma.